Orexo enhances commercial focus and operating efficiencies

Uppsala, Sweden – August 20, 2014 – Orexo AB (publ) announces today that the
company is taking further steps to enhance commercial focus, agility and
operating efficiency. The sales development of Zubsolv® continues to evolve
positively with the tablet sales increasing 64% in volume the last four weeks
compared to the last month of the second quarter. The market share has improved
from 2.3% in June to 3.9% in the first week of August. This positive sales
development is primarily driven by improvements in Zubsolv’s market access
position and the exclusive contract with UnitedHealth Group in particular.

The improvement in market access continues to progress well, and Orexo is
pleased to announce that the largest commercial payer, the PBM Express Script
(ESI), will place Zubsolv on their preferred formulary effective January 1,
2015. In addition, many public payers are improving the reimbursement of Zubsolv
in several large states such as Michigan, Texas and California. With the
improved market access, additional 991 physicians have prescribed Zubsolv for
the first time after July 1 and market share has increased in several sales
districts. The prescriptions of Zubsolv are on a four week basis growing double
digit for patients in all payer segments, with exception of FFS Medicaid
accounting for around 10% of the market. Within the commercial payer segment,
the market share exceeds 5% in two thirds of the districts and 10% of new
prescriptions in several sales districts.

As a next step to improve operating efficiency, Orexo has taken the decision to
place all manufacturing of Zubsolv at our partners in the US and streamline the
operations in Uppsala. The facilities in Uppsala will focus on new product
development, product maintenance and global external sourcing and supply, and
continue as the global headquarter for Orexo AB. Additionally, Orexo is
revisiting the operating model within research and development to increase
flexibility and agility in development of new products and life cycle
activities. These adjustments in Orexo’s operating model could result in
approximately 15 positions being identified as redundant at the facilities in
Uppsala, Sweden. The restructuring of the Swedish operations is expected to be
completed during the fourth quarter of 2014 and will be associated with
restructuring costs of approx. MSEK 7 during the same quarter and an annual cost
saving of around MSEK 10-15, with a positive impact beginning already in the
first quarter of 2015.

“During the last year, Orexo has successfully established commercial operations
in the US and the focus has been entirely on the launch of Zubsolv. We are
pleased with the sales improvements during the summer and are excited about the
continuing improvements in market access. Now it is time to ensure we have the
optimal operating model for the future, with the appropriate focus and agility
necessary to develop the next generation in the Zubsolv line and other new
products. This new operating model will build more on external partnerships to
ensure we complement our excellent and proven internal development team with
leading international expertise. This important change increases Orexo’s ability
to flex its resources within development more swiftly while enhancing our
ability to develop new products” says Nikolaj Sørensen, CEO and President of
Orexo AB.

For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: +46 (0)703-50 78 88, E-mail: ir@orexo.com

About Orexo AB
Orexo is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary drug
delivery technology and commercial operations in the United States. The company
is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for
maintenance treatment of opioid dependence, in the United States. The ZUBSOLV®
sublingual tablet is a novel formulation of buprenorphine and naloxone using
Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of
two approved and revenue generating products currently marketed under license in
the US, EU and Japan. Orexo AB, with its headquarters in Sweden, is listed on
NASDAQ OMX Stockholm Exchange and its American Depositary Receipts (ADRs) trade
on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest
shareholders are Novo A/S and HealthCap.

For information about Orexo, please visit www.orexo.com.

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 11:00am CET on August 20, 2014.